$7.81

0.36 (4.83%)

11/21/2008 4:00 PM

Salix Pharmaceuticals, Ltd. (SLXP)

CAPS Rating:

A pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SLXP

Add Stock to Watchlist

What the Community Thinks

Total Members

77 Outperforms

17 Underperforms

All-Stars

22 Outperforms

4 Underperforms

Wall Street

1 Outperforms

1 Underperforms

Members bullish on SLXP are also bullish on:

Members bearish on SLXP are also bearish on:

Ticker Tags

Pharmaceuticals (148), Micro Cap (5043)
Suggest a tag

Salix Pharmaceuticals, Ltd. At A Glance

Current Price:	$7.81
Last Trade Time:	11/21/2008 4:00 PM
Open:	$7.56
Previous Close:	$7.45
Daily Range:	$6.92 - $8.03
52-Week Range:	$5.07 - $12.42
Volume:	2,437,503
Market Cap:	$358.06M
P/E Ratio:	41.71
Compare Our Special Broker Offers!

Stock Trends

SLXP VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for SLXP

Hewlett-Packard, Home Depot, Saks among big movers
11/18/2008 4:29:00 PM - AP
Salix drug receives patent for potential new use
11/18/2008 12:13:00 PM - AP
Salix says IBS drug candidate met goal in study
10/6/2008 11:00:00 AM - AP
Salix Pharmaceuticals sues Novel over patent
9/9/2008 8:00:00 AM - AP

More Headlines...

Top Bull Pitch

Recs

0 Salix Pharmaceuticals, Ltd. (SLXP)

Avatar tenmiles (99.99) Submitted: 12/28/07 3:11 PM

Looks like time to go long Salix.

Large short position in company and they have had their way of late. At current $10 range, stock offers strong value - mid teen ROE, strong balance sheet and good growth prospects including potential XIFAXAN. Current price discounts most un...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 15 : 1 2 3 Next »

Recs 0 (SLXP) FutbalRef (< 20) Submitted: 9/05/08 2:49 PM : Start Price: $6.65 SLXP Score: 56.53 Their stock took a big hit a few months back when the FDA asked for more data on one of their drug trials. They have some drugs in their pipeline (stage 3 trials) that will cause the stock to recover as long as some of them pass. Undervalued at the current price. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (SLXP) reidmp (79.23) Submitted: 6/12/08 10:57 AM : Start Price: $7.05 SLXP Score: 54.85 Over-reaction to FDA asking for more data after other problems. There have been too many high-profile drug safety stories in the media and it is logical to expect it will cause the FDA to be more cautious in handing out approvals. Solid insider purchasing and the recent trading pattern seems very stable and moving upward in a way that is much less erratic than seen in many biotech stocks. Approval will help offset the genericization of COLAZAL. Also, Inflammatory diseases need better media coverage and consumer education. There is huge potential for improving quality of life for cronic conditions that can, without effective long-term management, shorten life expectancy. This could be a good company to monitor in that space. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (SLXP) caseykimma (79.00) Submitted: 4/07/08 10:56 PM : Start Price: $7.09 SLXP Score: 54.49 several months or more..took a big hit in Jan08, slowly gaining back..Yahoo screener pick Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (SLXP) leadbuilder (43.92) Submitted: 3/20/08 3:20 PM : Start Price: $6.60 SLXP Score: 61.21 Good Management and moving in the right direction Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (SLXP) Foxyprox (84.20) Submitted: 2/12/08 4:37 PM : Start Price: $6.58 SLXP Score: 62.94 Highly undervaled, great bargain in long run. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 15 : 1 2 3 Next »

Wall Street

Results 1 - 2 of 2

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackZacks	77.13	10/20/08		3M	$7.47	+4.55%	-23.25%	-27.80
	TrackPiperJaff	< 20	12/31/07		NS	$8.24	-5.22%	-48.45%	-43.23
	TrackSoros	< 20	09/30/07		NS	$12.42	-37.12%	-50.30%	+13.18

Results 1 - 2 of 2

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.